Dr. Reddy's Laboratories Limited to Present at the J.P. Morgan 35th Annual Healthcare Conference

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will present at the J.P. Morgan 35th Annual Healthcare Conference on Tuesday, January 10th, 2017, in San Francisco.

The presentation is scheduled to begin at 2:30 p.m. PST [4:00 a.m. IST on January 11th, 2017].

Presentation material will be available on the Company’s website www.drreddys.com.

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, Russia & CIS and India. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may," "will," "should," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170109005813/en/

Dr. Reddy's Laboratories Ltd.
INVESTOR RELATIONS
Saunak Savla, +91-40-49002135
[email protected]
or
MEDIA RELATIONS
Calvin Printer, +91-40-49002121
[email protected]

Source: Dr. Reddy’s Laboratories Ltd.

You May Also Be Interested In

• Dr. Reddy's Laboratories Ltd. (DRRD:IN) (RDY) PT Lowered to INR5,700 at Goldman Sachs
• Udemy Named to TIME’s Inaugural List of the World’s Top EdTech Companies in 2024
• Results of the Annual General Meeting 2024